Lantheus Holdings, Inc. (LNTH) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given a consensus rating of “Buy” by the six brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $18.75.
A number of equities analysts have weighed in on the company. Zacks Investment Research lowered Lantheus Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, September 20th. BidaskClub lowered Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 17th. Jefferies Group LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Lantheus Holdings in a research note on Thursday, October 12th. Cantor Fitzgerald assumed coverage on Lantheus Holdings in a research note on Monday, July 17th. They set an “overweight” rating and a $22.00 price objective for the company. Finally, Credit Suisse Group lifted their price objective on Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, August 2nd.
In other news, Director Derace L. Schaffer sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $17.50, for a total transaction of $262,500.00. Following the sale, the director now directly owns 48,730 shares in the company, valued at approximately $852,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO John W. Crowley sold 6,755 shares of the firm’s stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $18.41, for a total value of $124,359.55. The disclosure for this sale can be found here. Insiders have sold a total of 903,099 shares of company stock worth $15,443,485 over the last 90 days. Insiders own 2.30% of the company’s stock.
Large investors have recently bought and sold shares of the company. Royce & Associates LP acquired a new stake in shares of Lantheus Holdings during the 2nd quarter valued at about $4,896,000. QS Investors LLC acquired a new stake in Lantheus Holdings in the 2nd quarter worth about $2,256,000. Bank of New York Mellon Corp boosted its holdings in Lantheus Holdings by 6.3% in the 1st quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock worth $856,000 after buying an additional 4,084 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Lantheus Holdings in the 2nd quarter worth about $835,000. Finally, California Public Employees Retirement System boosted its holdings in Lantheus Holdings by 29.2% in the 1st quarter. California Public Employees Retirement System now owns 77,800 shares of the medical equipment provider’s stock worth $973,000 after buying an additional 17,600 shares during the last quarter. Hedge funds and other institutional investors own 85.03% of the company’s stock.
Lantheus Holdings (NASDAQ LNTH) opened at 19.10 on Tuesday. The stock has a 50 day moving average price of $17.85 and a 200-day moving average price of $17.81. The company has a market cap of $713.39 million, a price-to-earnings ratio of 26.09 and a beta of 0.91. Lantheus Holdings has a 1-year low of $7.95 and a 1-year high of $19.45.
Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.18. The business had revenue of $88.83 million during the quarter, compared to analyst estimates of $80.56 million. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. The company’s revenue was up 13.9% on a year-over-year basis. During the same quarter last year, the business posted $0.24 EPS. On average, equities research analysts forecast that Lantheus Holdings will post $1.12 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Lantheus Holdings, Inc. (LNTH) Receives Consensus Recommendation of “Buy” from Brokerages” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/31/lantheus-holdings-inc-lnth-receives-consensus-recommendation-of-buy-from-brokerages.html.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.